CN102516258B - 水溶性维生素e衍生物修饰的脂溶性抗癌药物化合物和制剂、该化合物的制备方法及应用 - Google Patents
水溶性维生素e衍生物修饰的脂溶性抗癌药物化合物和制剂、该化合物的制备方法及应用 Download PDFInfo
- Publication number
- CN102516258B CN102516258B CN201110355747.5A CN201110355747A CN102516258B CN 102516258 B CN102516258 B CN 102516258B CN 201110355747 A CN201110355747 A CN 201110355747A CN 102516258 B CN102516258 B CN 102516258B
- Authority
- CN
- China
- Prior art keywords
- ester
- cancer drug
- fat
- drug compounds
- alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*1CCN(C)CC1 Chemical compound C*1CCN(C)CC1 0.000 description 5
- LLZHFVMKOUYYBO-UHFFFAOYSA-N CC(C1)C1(C(C=C1N2Cc3cc(cccc4)c4nc13)=C(CO1)C2=O)C1=O Chemical compound CC(C1)C1(C(C=C1N2Cc3cc(cccc4)c4nc13)=C(CO1)C2=O)C1=O LLZHFVMKOUYYBO-UHFFFAOYSA-N 0.000 description 1
- RINCXYDBBGOEEQ-UHFFFAOYSA-N O=C(CC1)OC1=O Chemical compound O=C(CC1)OC1=O RINCXYDBBGOEEQ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
- C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Abstract
Description
Claims (7)
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110355747.5A CN102516258B (zh) | 2011-11-11 | 2011-11-11 | 水溶性维生素e衍生物修饰的脂溶性抗癌药物化合物和制剂、该化合物的制备方法及应用 |
CN201410229587.3A CN104003996B (zh) | 2011-11-11 | 2011-11-11 | 水溶性维生素e衍生物修饰的脂溶性抗癌药物化合物和制剂、该化合物的制备方法及应用 |
EP12847433.5A EP2799438B1 (en) | 2011-11-11 | 2012-10-18 | Water-soluble vitamin e derivative modified fat-soluble anti-cancer drug compound and formulation, preparation method and use thereof |
AU2012334620A AU2012334620B2 (en) | 2011-11-11 | 2012-10-18 | Trolox derivative-modified fat-soluble anti-cancer pharmaceutical compounds, preparations, preparing methods and use thereof |
JP2014540301A JP5782569B2 (ja) | 2011-11-11 | 2012-10-18 | トロロックス誘導体修飾脂溶性抗がん剤化合物、ならびにその製剤、製造方法および使用 |
US14/357,560 US9206192B2 (en) | 2011-11-11 | 2012-10-18 | Trolox derivative-modified fat-soluble anti-cancer pharmaceutical compounds, preparations, preparing methods and use thereof |
CA2855180A CA2855180C (en) | 2011-11-11 | 2012-10-18 | Trolox derivative-modified fat-soluble anti-cancer pharmaceutical compounds, preparations, preparing methods and use thereof |
PCT/CN2012/083161 WO2013067882A1 (zh) | 2011-11-11 | 2012-10-18 | 水溶性维生素e衍生物修饰的脂溶性抗癌药物化合物和制剂、该化合物的制备方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110355747.5A CN102516258B (zh) | 2011-11-11 | 2011-11-11 | 水溶性维生素e衍生物修饰的脂溶性抗癌药物化合物和制剂、该化合物的制备方法及应用 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410229587.3A Division CN104003996B (zh) | 2011-11-11 | 2011-11-11 | 水溶性维生素e衍生物修饰的脂溶性抗癌药物化合物和制剂、该化合物的制备方法及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102516258A CN102516258A (zh) | 2012-06-27 |
CN102516258B true CN102516258B (zh) | 2014-06-25 |
Family
ID=46287377
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110355747.5A Active CN102516258B (zh) | 2011-11-11 | 2011-11-11 | 水溶性维生素e衍生物修饰的脂溶性抗癌药物化合物和制剂、该化合物的制备方法及应用 |
Country Status (7)
Country | Link |
---|---|
US (1) | US9206192B2 (zh) |
EP (1) | EP2799438B1 (zh) |
JP (1) | JP5782569B2 (zh) |
CN (1) | CN102516258B (zh) |
AU (1) | AU2012334620B2 (zh) |
CA (1) | CA2855180C (zh) |
WO (1) | WO2013067882A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105315294B (zh) * | 2014-06-26 | 2018-05-01 | 王杭祥 | 7-乙基-10-羟基喜树碱药物前体及其制备方法和应用 |
WO2017097197A1 (zh) * | 2015-12-08 | 2017-06-15 | 正大天晴药业集团股份有限公司 | 美西替康的药物组合物 |
EP3388055B1 (en) * | 2015-12-08 | 2021-11-17 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Method for preparing liposome |
WO2017127559A1 (en) * | 2016-01-19 | 2017-07-27 | H.B. Fuller Company | One-part polyurethane adhesive composition, method of making a laminate, and laminate |
CN107903258B (zh) * | 2017-11-13 | 2021-03-19 | 中南大学湘雅三医院 | 一种脂溶性光敏剂及其制备方法和应用 |
JP2021095424A (ja) * | 2018-03-28 | 2021-06-24 | 持田製薬株式会社 | 抗癌剤結合アルギン酸誘導体 |
CA3146510A1 (en) | 2019-07-11 | 2021-01-14 | Sun Pharma Advanced Research Company Ltd. | Camptothecin derivatives with a disulfide moiety and a piperazine moiety |
CN111635390A (zh) * | 2020-06-30 | 2020-09-08 | 江南大学 | 一种低泡型α-生育酚表面活性剂及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1325303A (zh) * | 1998-09-23 | 2001-12-05 | 研究发展基金会 | 生良酚、生育三烯酚、其它苯并二氢吡喃和侧链衍生物,及其用途 |
CN1680402A (zh) * | 1998-08-07 | 2005-10-12 | 堪萨斯州立大学 | 位阻醇或酚的水溶性前药 |
CN1875022A (zh) * | 2003-10-29 | 2006-12-06 | 搜讷斯医药股份有限公司 | 生育酚修饰的治疗性药物化合物 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995008986A1 (en) * | 1993-09-27 | 1995-04-06 | Smithkline Beecham Corporation | Camptothecin formulations |
US6350756B1 (en) * | 2001-01-18 | 2002-02-26 | California Pacific Medical Center | Camptothecin derivatives |
US20080045559A1 (en) * | 2003-10-29 | 2008-02-21 | Sonus Pharmaceuticals, Inc. | Tocopherol-modified therapeutic drug compounds |
KR20060110872A (ko) * | 2003-10-29 | 2006-10-25 | 소너스파머슈티칼즈인코포레이티드 | 토코페롤 변성 치료제 약물 화합물 |
ITRM20040240A1 (it) * | 2004-05-13 | 2004-08-13 | Ist Naz Stud Cura Dei Tumori | Camptotecine coniugate in posizione 7 con antagonisti delle integrine. |
JP4826133B2 (ja) * | 2005-04-28 | 2011-11-30 | 三菱瓦斯化学株式会社 | S−(−)−6−ヒドロキシ−2,5,7,8−テトラメチルクロマン−2−カルボン酸及びその製造方法 |
JP5564512B2 (ja) * | 2008-11-24 | 2014-07-30 | セダーズ−シナイ メディカル センター | 抗酸化カンプトセシン誘導体及びその抗酸化、抗新生物ナノスフェア |
CN102491981B (zh) * | 2011-11-11 | 2014-11-19 | 南京美西宁医药科技有限责任公司 | 水溶性维生素e衍生物修饰的双亲性抗癌药物化合物和制剂、该化合物的制备方法及应用 |
-
2011
- 2011-11-11 CN CN201110355747.5A patent/CN102516258B/zh active Active
-
2012
- 2012-10-18 WO PCT/CN2012/083161 patent/WO2013067882A1/zh active Application Filing
- 2012-10-18 EP EP12847433.5A patent/EP2799438B1/en active Active
- 2012-10-18 CA CA2855180A patent/CA2855180C/en active Active
- 2012-10-18 JP JP2014540301A patent/JP5782569B2/ja active Active
- 2012-10-18 AU AU2012334620A patent/AU2012334620B2/en active Active
- 2012-10-18 US US14/357,560 patent/US9206192B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1680402A (zh) * | 1998-08-07 | 2005-10-12 | 堪萨斯州立大学 | 位阻醇或酚的水溶性前药 |
CN1325303A (zh) * | 1998-09-23 | 2001-12-05 | 研究发展基金会 | 生良酚、生育三烯酚、其它苯并二氢吡喃和侧链衍生物,及其用途 |
CN1875022A (zh) * | 2003-10-29 | 2006-12-06 | 搜讷斯医药股份有限公司 | 生育酚修饰的治疗性药物化合物 |
Non-Patent Citations (2)
Title |
---|
Eva-Maria Collnot,等.Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers.《Journal of Controlled Release》.2006,第111卷(第1-2期),第35-40页. * |
JP特开2006-306809A 2006.11.09 |
Also Published As
Publication number | Publication date |
---|---|
CA2855180A1 (en) | 2013-05-16 |
CA2855180C (en) | 2016-06-14 |
AU2012334620A1 (en) | 2014-07-03 |
EP2799438A1 (en) | 2014-11-05 |
AU2012334620B2 (en) | 2017-02-09 |
US20140343088A1 (en) | 2014-11-20 |
US9206192B2 (en) | 2015-12-08 |
WO2013067882A1 (zh) | 2013-05-16 |
EP2799438A4 (en) | 2015-05-27 |
JP5782569B2 (ja) | 2015-09-24 |
JP2014532733A (ja) | 2014-12-08 |
CN102516258A (zh) | 2012-06-27 |
EP2799438B1 (en) | 2016-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102516258B (zh) | 水溶性维生素e衍生物修饰的脂溶性抗癌药物化合物和制剂、该化合物的制备方法及应用 | |
US7786164B2 (en) | Lipophilic di(anticancer drug) compounds, compositions, and related methods | |
US20050096340A1 (en) | Tocopherol-modified therapeutic drug compounds | |
Koudelka et al. | Liposomes with high encapsulation capacity for paclitaxel: Preparation, characterisation and in vivo anticancer effect | |
CN101897976A (zh) | 一种药物增溶载体及其制备方法和应用 | |
CN102491981B (zh) | 水溶性维生素e衍生物修饰的双亲性抗癌药物化合物和制剂、该化合物的制备方法及应用 | |
WO2015110040A1 (zh) | 苯丁酸氮芥衍生物、制备方法及应用 | |
US10406239B2 (en) | Water-soluble docetaxel anticancer drug compound and preparation method and use thereof | |
CN108836937A (zh) | 顺铂纳米药物制剂、制备方法和应用 | |
CN1875022B (zh) | 生育酚修饰的治疗性药物化合物 | |
CN104003996A (zh) | 水溶性维生素e衍生物修饰的脂溶性抗癌药物化合物和制剂、该化合物的制备方法及应用 | |
WO2023091168A1 (en) | Formulated and/or co-formulated nanocarriers compositions containing immunogenic cell death (icd) inducing prodrugs useful in the treatment of cancer and methods thereof | |
CN106554329B (zh) | 水溶性紫杉醇抗癌药物化合物及其制备方法和应用 | |
CN109574960B (zh) | 一种多西他赛衍生物及其制备方法和应用 | |
CN109336850A (zh) | 烷基醇修饰的多西他赛衍生物抗癌药物化合物及其制备方法和应用 | |
CN103965208B (zh) | 亲脂性的醇或酚修饰的脂溶性喜树碱类抗癌药物化合物和制剂、该化合物的制备方法及应用 | |
CN103965208A (zh) | 亲脂性的醇或酚修饰的脂溶性喜树碱类抗癌药物化合物和制剂、该化合物的制备方法及应用 | |
CN110845452A (zh) | 一种卡巴他赛衍生物及其制备方法和应用 | |
CN113698589B (zh) | 一种维生素e琥珀酸酯磷脂化合物及其应用 | |
CN109381427A (zh) | 一种寡聚乙二醇修饰的多西他赛衍生物的注射剂 | |
WO2010118200A2 (en) | Liposomal formulations of tocopheryl amides | |
CA3194742A1 (en) | Formulated and/or co-formulated liposome compositions containing pd-1 antagonist prodrugs useful in the treatment of cancer and methods thereof | |
CN117247389A (zh) | 一种靶向药物化合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: JIANGSU ZHENGDA TIANQING PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: NANJING MEIXINING MEDICAL TECHNOLOGY CO., LTD. Effective date: 20130201 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210009 NANJING, JIANGSU PROVINCE TO: 210023 LIANYUNGANG, JIANGSU PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20130201 Address after: 210023 No. 8 Julong North Road, Sinpo District, Jiangsu, Lianyungang Applicant after: Jiangsu Chiatai Tianqing Pharmaceutical Co., Ltd. Address before: 210009, science and technology innovation building, 5 new exemplary Road, Gulou District, Jiangsu, Nanjing A1818 Applicant before: Nanjing Meixining Medical Technology Co., Ltd. |
|
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: 210023 No. 8 Julong North Road, Sinpo District, Jiangsu, Lianyungang Applicant after: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Address before: 210023 No. 8 Julong North Road, Sinpo District, Jiangsu, Lianyungang Applicant before: Jiangsu Chiatai Tianqing Pharmaceutical Co., Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: JIANGSU ZHENGDA TIANQING PHARMACEUTICAL CO., LTD. TO: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |